Purity ≥ 99%GLP-3 (RT) Synthetic peptide analog
- Synthetic peptide
- ≥99% purity
- CoA per lot
Analytical-grade peptide reference material, supplied as a lyophilized powder for in-vitro laboratory research use only.
Bundle and bulk savings, codes and shipping are worked out in the cart at VNG.
Free shipping over $149 · CoA included with every order
What it is
A single-molecule triple agonist targeting the GLP-1, GIP, and glucagon receptors — the newest generation of incretin-based research compounds, studied as a successor to dual GLP-1/GIP agonists.
How it is studied
By activating all three receptors at once, it is investigated for a combined effect on appetite signaling, insulin response, and energy expenditure — a broader mechanism than GLP-1-only compounds.
Research areas
Metabolic regulation, body composition and energy-expenditure research.
Lab report for every lot
Each lot ships with a Certificate of Analysis matched to its lot number: purity, identity, heavy metals, sterility and endotoxin.
Published research
- Retatrutide for obesity — Phase 2 trialThe New England journal of medicine, 2023
- Retatrutide in obesity pharmacotherapyBiomolecules, 2025
- Retatrutide in obesity and diabetes therapyEuropean journal of pharmacology, 2024
- Retatrutide for type 2 diabetes — Phase 2 trialLancet (London, England), 2023
- Retatrutide for fatty liver disease — Phase 2a trialNature medicine, 2024
- Retatrutide for obesity — systematic review & meta-analysisProceedings (Baylor University. Medical Center), 2025
- Retatrutide on weight & metabolic markers — meta-analysisMetabolism open, 2024
- Retatrutide — TRIUMPH clinical trial programDiabetes, obesity & metabolism, 2026
Research use only. Not for human or animal consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.
